Introduction
Women with proliferative disorders of increasing severity (atypical hyperplasias to in situ carcinomas to invasive carcinomas) are at an increased risk of subsequent breast cancer development when compared to women with normal epithelium or those with proliferative disorders lacking atypia (Dupont and Page, 1985) . Thus, it appears that mammary tumorigenesis, like colorectal tumor formation (Fearon and Vogelstein, 1990; Vogelstein and Kinzler, 1993) , may arise in a step-wise fashion involving the acquisition of several distinct genetic perturbations each contributing to full malignancy. Mammary tumors are graded into four morphological groups, each having characteristic disease and clinical outcomes. Karyotypic and epidemiological analyses of these stages suggest that breast carcinoma become increasingly aggressive due to the acquisition of several successive distinct genetic changes (Dupont and Page, 1985) . Genetically these alterations can be loosely grouped into two large categories: gain of function and loss of function mutations.
Gain of function alterations occur in protooncogenes, whose products are involved in sustaining or promoting cell growth and survival. A number of genes are ampli®ed and/or overexpressed in human mammary tumors. These include growth factor like molecules (int2: Schuuring et al., 1992; Zhou et al., 1988) , growth factor receptors (EGFR: Gasparini et al., 1992; Sainsbury et al., 1988 , c-ErbB2: Slamon et al., 1987 , 1989 , other tyrosine kinases (Jacobs and Rubsamen, 1983; Ottenho-Kal et al., 1992; , signaling molecules (GRB7 Stein et al., 1994) , transcription factors (c-myc: Berns et al., 1992) and cell cycle regulators (cyclin D1/PRAD-1: Bartkova et al., 1994; Buckley et al., 1993 , CDC25B: Galaktionov, 1995 . While several genes are ampli®ed in each amplicon (or at each locus), three candidates may be relevant to human disease (erbB-2, c-myc and cyclin D respectively). Transgenic mice bearing/overexpressing these proto-oncogenes have tested their transforming potential within the mammary gland (reviewed in Dankort and Muller, 1996) .
Loss of function mutations occur within so called tumor suppressor' genes, which function to ultimately prevent unrestrained growth. Mutations of tumor suppressor genes render their products inactive and are thus are genetically recessive. Interestingly, the encoded proteins aect cell growth and survival in a variety of ways. Some negatively regulate cell cycle progression, restricting G1-S transition. Examples include the retinoblastoma (Rb) protein and the p21 and p16 family of cyclin dependent kinase inhibitors. Others are involved in the maintenance of DNA replication ®delity through DNA repair proteins like RAD51. Finally, tumor suppressor proteins such as p53, appear to monitor genetic integrity and when an unacceptable level of damage has been sustained, initiate programmed cell death.
ErbB-2 plays a causal role in mammary tumorigenesis
ErbB-2, a member of the epidermal growth factor (EGF) receptor tyrosine kinase (RTK) family, is overexpressed in 20 ± 30% of primary human breast cancers (Slamon et al., 1987; 1989 reviewed in Hynes and Stern, 1994) . Moreover, ampli®cation and consequent overexpression prognosticates a poor clinical prognosis in both lymph node positive (Hynes and Stern, 1994; Mansour et al., 1994; Ravdin, 1995) and node-negative (Andrulis et al., 1998) breast cancer patients. It is felt that ErbB-2 overexpression leads to an aggressive tumor phenotype as elevated ErbB-2 expression is detected in many in situ and invasive human ductal carcinomas, yet is rarely observed in benign breast disorders (hyperpla-*Correspondence: WJ Muller sias and dysplasias) (Allred et al., 1992; reviewed in Mansour et al., 1994) .
Direct evidence supporting a role for erbB-2 in mammary tumorigenesis derives from studies with transgenic mice. To directly test the importance of erbB-2 in mammary tumorigenesis, transgenic mice carrying an activated form of the erbB-2/neu oncogene under the transcriptional control of the mouse mammary tumor virus long terminal repeat were derived. Mammary epithelial speci®c-expression of a constitutively active ErbB-2 or a similarly altered human erbB-2 in the mammary epithelium of transgenic mice (Bouchard et al., 1989; Guy et al., 1996; Luchini et al., 1992; Muller et al., 1988; Stocklin et al., 1993) results in the rapid induction of mammary tumors that histologically resemble human comedocarcinomas (Cardi and Muller, 1993) . Interestingly, human comedo-carcinomas express elevated ErbB-2 levels (Morrison, 1994) , have a higher proliferative rate and are clinically more severe than other ductal carcinoma in situ (Patchefsky et al., 1989) .
While these data are intriguing, examination of many human breast cancer biopsies have failed to reveal a comparable activating mutation, suggesting that the overexpression of wild-type receptors is responsible for erbB-2-induced tumors (Lemoine et al., 1990; Slamon et al., 1989; Zoll et al., 1992) . Transgenic mice expressing elevated levels of wild-type ErbB-2 develop focal breast tumors of similar comedotype morphology at an increased latency and these tumors frequently metastasized to the lung (Guy et al., 1992b) . Although the levels of ErbB-2 protein in normal and tumor tissues appear to be similar in several matched samples, biochemical analyses of these tumors revealed that the tumor epithelia possess elevated levels of tyrosine phosphorylated ErbB-2 compared to adjacent epithelium. One potential explanation for these observations is that tumor progression in these strains involved the acquisition of activating mutations in the erbB-2/neu transgene. Indeed, genetic analyses revealed that the majority of tumors arise due to somatic mutation of the transgene . Multiple in frame deletions, insertions or point mutations in the extracellular domain were detected in tumors but not the adjacent hyperplastic epithelium. Moreover, mammary speci®c expression of these extracellular ErbB-2 deletions leads to multifocal tumor formation, with an average onset between that observed for mice bearing the normal and point activated alleles (Siegel et al., 1999) . Whereas there is no evidence of somatic mutation within the erbB-2 oncogene, recent studies have suggested that alternative splice form of erbB-2 possessing oncogenic activity may be involved in the induction of human breast cancer. This alternative splice form possesses a 16 amino acid deletion in the juxtatransmembrane region of ErbB-2 that bears remarkable similarity to the sporadic mutations in the MMTV/erbB-2 strains. Indeed, like the sporadic deletion variants, this splice isoform possesses transforming activity due to its capacity to form disul®de bonded dimers (Siegel et al., 1999) . One possible explanation for the frequent occurrence of somatic mutations in the transgene in the MMTV/wild type erbB-2 mice is that due to the fact that mice express the erbB-2 cDNA, this alternative splice cannot be generated and consequently sporadic deletions mimicing this splice form are selected. Given the strong biological selection occurring in this transgenic model, the expression of this novel splice variant may play a critical role in the induction of human breast cancer.
Expression of other members of the EGFR family are involved in ErbB-2/Neu induced mammary tumorigenesis While these systems have clearly de®ned a causal role of ErbB-2 in the generation of breast cancers, the molecular mechanism by which tumor progression in these strains is unclear. ErbB-2 mediated signal transduction is further complicated by the fact that its activity can be in¯uenced by activation by other members of the epidermal growth factor receptor (EGFR) family including EGFR, ErbB-3 and ErbB-4 (reviewed in Tzahar and Yarden, 1998) . For example, EGFR speci®c ligands including EGF and transforming growth factor a (TGFa), although not able to directly interact with ErbB-2 can transphorylate ErbB-2 through formation of speci®c ErbB-2/EGFR heterodimer. Similarly, ErbB-2 can be transphorylated by either ErbB-3 and ErbB-4 following the stimulation of mammary tumor cell lines with Neuregulins which are speci®c ligands for ErbB-2 and ErbB-4. By contrast, no direct ligand has been cloned for ErbB-2 although several activities have been puri®ed for some time (Dobashi et al., 1991; Lupu et al., 1992; Samanta et al., 1994; Wu et al., 1994; Heldin, 1995; Tzahar and Yarden, 1998) .
Overexpression of EGFR or ErbB-3/4 -speci®c ligands is associated with mammary tumorigenesis. Expression of TGFa in the mammary gland by virtue of the MMTV-LTR or metallothionein promoters causes epithelial hyperplasia and dysplasia and, in rare cases, results in tubular mammary tumors adenocarcinomas (Matsui et al., 1990; Sandgren et al., 1990) . Additionally, multiparous animals expressing a member of the NRG family of ligands (NDFb2) develop palpable mammary tumors at long latencies and low penetrance (Krane and Leder, 1996) . While these studies indicate that overexpression of the tested ErbB ligands is insucient for rapid mammary tumorigenesis, coexpression of TGFa and normal ErbB-2 in bitransgenic animals has a synergistic eect . Bitransgenic animals rapidly acquire multifocal mammary tumors characteristic of TGFa or ErbB-2 expression with increased penetrance (95% TGFa/Neu versus 6% TGFa and 35% Neu at 250 days). While ErbB-2 appeared to be active in bitransgenic tumors, there was little evidence of the ErbB-2 transgene mutation seen in monotransgenic MMTV-ErbB-2 animals, suggesting TGFa coexpression was sucient to transactivate the receptor, presumably through the EGFR.
More recently, immunoblot analyses of mammary tumors from activated MMTV/erbB-2 strains has revealed that there was a dramatic elevation of ErbB-3 protein during tumor progression (Siegel et al., 1999) . Interestingly, genetic and biochemical analyses of revealed that this dramatic upregulation of ErbB-3 protein occurred at the level of protein translation or stability rather than at the transcript level. Although the biological signi®cance of this upregulation of ErbB-3 in mammary tumor progression is unclear, it intriguing that ErbB-3 appears to be involved in recruitment of the phosphatidylinositol 3' (PI-3') kinase signaling pathway to ErbB-2. Given the recent data implicating this signaling pathway as an important anti-apoptotic signaling pathway, elevated ErbB-3 expression may result in activation of this cell survival pathway during mammary tumor progression.
Signaling from the ErbB-2/Neu receptor kinase and polyomavirus middle T antigen
In response to ligand binding, these class I RTKs become heavily phosphorylated predominantly at discrete tyrosine residues within a 200 ± 300 amino acid carboxyl-terminal region through auto-and transphosphorylation of dimers. The primary function of RTK tyrosine phosphorylation is to generate binding sites for cytoplasmic or plasma membrane associated proteins involved in transducing proliferative or dierentiating signals to the nucleus. These`signaling proteins' each contain modular Src homology 2 (SH2) (Sadowski et al., 1986) or protein tyrosine binding/ interacting (PTB/PID) (van der Geer et al., 1995) domains and directly interact with phosphotyrosyl proteins in a sequence speci®c manner (reviewed in Pawson and Scott, 1997; Sudol 1998) . Such signaling proteins can be loosely grouped into two classes: enzymes and non-enzymatic`adapter' proteins.
ErbB family members directly interact with a diverse set of signaling proteins harboring enzymatic activities which include protein tyrosine kinase (Src family PTKs) and phosphatase (Shp1/2) activities, enzymes involved in phospholipid metabolism (phospholipases (PLCg)) as well as STAT transcription factors. Adapter proteins such as the p85 regulatory subunit of phosphatidylinositol 3'OH kinase (PI3'K) and the growth factor bound 2 (Grb2) protein respectively couple these receptors to enzymes which modulate lipid phosphorylation (p85 to the 110 kDa catalytic PI3'K) or Ras GTPase activity (Grb2 to the Ras exchange factor Sos). Although many reports itemize the signaling proteins which interact with dierent ErbB receptors, the role each molecule plays in transducing a proliferative, transforming or dierentiating signal is less clear. PLCg1 (Fazioli et al., 1991; Jallal et al., 1992; Segetto et al., 1992) , c-Src (Luttrell et al., 1994; Muthuswamy and Muller, 1995; Muthuswamy et al., 1994) , Crk (Dougall et al., 1996) and Grb7 (Stein et al., 1994) interact with ErbB-2 through speci®c phosphotyrosine residues. PI3K activity associates with ErbB-2 but likely does so through p85 adapter subunit interactions with tyrosine phosphorylated ErbB-3 (Peles et al., 1992; Scott et al., 1991, see below) . An additional set of SH2-containing proteins that associate with ErbB-2/Neu include Ras-GAP (Fazioli et al., 1991; Jallal et al., 1992) , Shc (Segatto et al., 1992) , Grb2 (Janes et al., 1994) and Nck (Dougall et al., 1996) . These latter proteins modulate the activity of Ras by either promoting the formation of an active Ras-GTP complex or by accelerating the hydrolysis of Ras-GTP to its inactive Ras-GDP state. Given the prevalence and presumed causality of ErbB-2 overexpression in human disease it is of paramount importance to determine the molecules ErbB-2 signals transformation through so as to provide rational targets for future therapeutic intervention.
Another tyrosine kinase associated with the induction of murine mammary cancers is that complexed to the Polyoma DNA tumor virus (PyV) middle T (MT) antigen. Infection of newborn or nu/nu mice with PyV frequently results in the induction of mammary tumors (Berebbi et al., 1990) , requiring a functional MT antigen to induce tumor formation (Israel et al., 1979) . PyV MT antigen lacks intrinsic biochemical activity (Kaplan et al., 1988) but rather exerts its oncogenic eects through its association with the c-Src PTKs (Cheng et al., 1988; Courtneidge and Smith, 1983; Kornbluth et al., 1986; Kypta et al., 1988) and other signaling molecules such as Shc and PI3'K. Indeed, genetic analysis of MT mutants de®cient in Src, PI3K or Shc interaction are invariably transformation incompetent (Campbell et al., 1994; Charmichel et al., 1984; Dilworth et al., 1994; Druker et al., 1992; Markland et al., 1986; reviewed in Markland and Smith, 1987) . Like MMTV/activated erbB-2 mice, animals bearing a MMTV/PyV MT transgene synchronously develop multifocal tumors with a short latency concurrent with detectable transgene expression (Guy et al., 1992a) suggesting that the activation of MT signaling pathways is sucient for mammary tumorigenesis.
Src family protein tyrosine kinases
Src PTK family activities (Src, Yes, Fyn) are elevated in human and murine primary breast carcinoma and cells derived thereof (Jacobs and Rubsamen, 1983; Muthuswamy et al., 1994; Ottenho-Kal et al., 1992; Rosen et al., 1996) . Additionally, cortactin, a v-Src substrate (Wu et al., 1991) , is the product of the EMS-1 locus (Schuuring et al., 1993) on human chromosome 11q13, a region frequently ampli®ed in malignant mammary carcinoma (Schuuring et al., 1992) . The importance of the c-Src signaling pathway in mammary tumorigenesis has been illustrated by several important transgenic studies. Germline inactivation of c-src but not c-yes in transgenic mice expressing the MMTV/ PyV MT transgene resulted in a dramatic inhibition of mammary tumor formation (Guy et al., 1994) . However, mammary epithelial expression of an activated c-src oncogene resulted in mammary epithelial hyperlasias which evolved into focal mammary tumors after a long latency period. (Webster et al., 1995) . Taken together, these observations suggest that while c-src is required for PyV MT induced mammary tumors, its activation is insucient to recapitulate the rapid tumor onset observed in the MMTV/PyV MT strains.
Activation of c-Src signal transduction pathway has also been implicated in ErbB-2 and EGFR induced mammary tumors (Luttrell et al., 1994; Muthuswamy and Muller, 1995; Muthuswamy et al., 1994) and is activated in response to activated ErbB-2 expression in ®broblasts (Muthuswamy and Muller, 1995) . Moreover, EGF-induced DNA synthesis, transformation and tumorgenicity are potentiated in cells expressing elevated c-Src levels (Luttrell et al., 1988; Maa et al., 1995) . Thus, while Src appears to play a role in ErbB-2 signaling, the nature of this relationship awaits further experimentation. Future crosses between the activated erbB-2 strains and c-Src knock out mice should allow this question to be addressed.
Ras activation
Ras proteins are evolutionarily conserved GTPases which play a pivotal role in a wide variety of cellular processes, and their importance in such phenomena has placed the regulation and mechanism of action of these proteins under intense research. These GTPases act as molecular switches, alternating between`inactive' GDPbound and`active' GTP-bound states through the cumulative activities of guanine nucleotide exchange factors (GEFs), which activate Ras through the exchange of GDP for GTP, and GTPase activating proteins (GAPs), which negatively regulate Ras through acceleration of Ras' intrinsic GTPase activity. GTPbound Ras interacts with and activates a number of eector proteins (reviewed in Campbell et al., 1998; Katz and McCormick, 1997) . Indeed, Ras mutations are found in many primary cancers, yet activating mutations are not considered to play a dramatic role in the etiology of breast carcinoma (Bos, 1989; Rochlitz et al., 1989) . Mammary-speci®c expression of oncogenic vHa-ras in transgenic mice induces mammary carcinomas, arising as solitary tumors which are histologically distinct from the ErbB-2-induced comedo-carcinomas (Andres et al., 1987; Nielsen et al., 1991; Sinn et al., 1987) . Until recently it has been dicult to assess tissue samples for Ras activation directly (Scheele et al., 1995) , yet Ras eector pathways are found activated in many breast cancers samples and derived cell lines, suggesting that Ras is activated in primary tumors. The lack of Ras activating mutations suggests that wild-type Ras is activated by the actions of RTKs such as ErbB members in breast tumors.
Activation of Ras by PyV MT antigen and ErbB-2 is accomplished, in part, through Grb2 and Shc adaptor protein recruitment of Sos GEFs to the plasma membrane. Grb2 contains a single SH2 domain anked by two SH3 domains, the later domain constitutively associates with Sos (Buday and Downward, 1993; Chardin et al., 1993; Egan et al., 1993; Gale et al., 1993; Li et al., 1993; Rozakis-Adcock et al., 1993) . Shc proteins are thought to promote Ras activation by indirectly recruiting Grb2 Rozakis-Adcock et al., 1992) through tyrosine phosphorylation of sites conforming to consensus Grb2 SH2 binding sites (Gotoh et al., 1997; Salcini et al., 1994; Songyang et al., 1994) . Ras activity is required for ecient ErbB-2 (Ben- Levy et al., 1994; Dankort et al., 1997) and PyV-MT-(Jelinek and Hassell, 1992) mediated signaling.
While none of the ®ve known ErbB-2 tyrosine phosphorylation sites are required for transformation (Segatto et al., 1990; Mikami et al., 1992; Ben-Levy et al., 1994; Dankort et al., 1997) , four sites (Y1144, Y1201, Y1226/7, Y1253) can independently mediate a transforming signal and require Ras activity to induce DNA synthesis (Dankort et al., 1997) . Of these Y1144 and Y1226/7 respectively bind Grb2 and Shc and interaction directly correlates with transformation potential, thus providing a molecular mechanism for Ras activation (Dankort and Muller, unpublished observations) . Moreover, transgene expression of ErbB-2 phosphorylation mutants capable of either direct Grb2 or Shc interaction develop mammary tumors that have distinct morphologies (Dankort and Muller, unpublished observations) .
Mammary speci®c expression of mutant PyV-MT molecules incapable of Shc association induces widespread mammary epithelial hyperplasias from which solitary tumors emerge. Interestingly, in 7% of the tumors that do arise, Shc binding is reconstituted via transgene mutation (Webster et al., 1998) . In fact, Shc binding sites are reconstituted in approximately 30% of the tested lung metastases. These data suggest that Shc association, and by inference Ras activation, leads to a more aggressive tumor phenotype. It is intriguing that the expression of mutant PyV-MT molecules which retain Shc binding develop mammary carcinoma which phenotypically resemble those in ErbB-2 expressing transgenics consistent with Ras' role in ErbB-2 mediated signaling. To determine the role Grb2 plays in MT induced carcinoma, the rate of mammary tumor formation was assessed in MMTV-PyV-MT transgenic animals containing a targeted grb2 mutation. Although a lack of Grb2 is incompatible with embryonic development (Cheng et al., 1998) , mice bearing a single functional grb2 allele develop breast tumors with a delayed onset relative to wild-type littermate controls. Thus, Ras activation through the Shc-Grb2 complex appears to play a critical role in the rapid generation of mammary tumors. In a number of mammary tumor cell lines, elevated Grb2 protein levels are found, often in complex with tyrosine phosphorylated Shc proteins Janes et al., 1994) . Moreover, Shc proteins are found tyrosine phosphorylated in all tested breast tumors analysed (Pellici et al., 1995) . Indeed, both Grb2 and Shc reside at chromosomal regions ampli®ed in human cancers .
Phosphatidylinositol 3-OH kinase (PI3'K) signaling in mammary tumorigenesis
In addition to proliferative signals emanating from RTKs or their eectors, there is a requirement for a concurrent`survival' or anti-apoptotic signal for ecient transformation. One important signaling molecule that has been implicated in cell survival is PI3'K. Stimulation of the PI3'K by activated growth factor receptors leads to the generation of 3'-phosphoinositide lipids, which can in turn stimulate AKT/PKB serine/threonine kinase, activated in part through the direct association with PI3'K phospholipid products through its PH domain. PI3K itself and Akt have been demonstrated to be involved in cellular survival, and under speci®c circumstances have anti-apoptotic properties (Dudek et al., 1997; Kennedy et al., 1997; Khwaja et al., 1997; Kuamann-Zeh et al., 1997; Kulik et al., 1997; Yao and Cooper, 1995) . While elevated levels of PI3K activity have been demonstrated in some cell lines overexpressing ErbB-2 (Peles et al., 1992; Scott et al., 1991) , it appears to be indirect and dependent on ErbB-3 levels (Almandi et al., 1995; Carraway III et al., 1995) . ErbB-3, contains six YxxM motifs in the carboxyl-tail and elevated PI3K activity is immunoprecipitated with antibodies to ErbB-3 but not EGFR or ErbB-2 in response to receptor activation (Solto et al., 1994; Wallasch et al., 1995) . Additionally, p85 associates with ErbB-3 in response to NDF/EGF and tyrosine phosphorylated peptides derived from these six potential p85 binding sites inhibit this association . As a result, it is thought that PI3K activity may play a role in Neu/ErbB-2 signaling, but does so through recruitment and phosphorylation of ErbB-3 (Sepp-Lorenzino et al., 1996) Further evidence for the importance of the PI3'K in mammary tumorigenesis stems from observations made with transgenic mice expressing mutant PyV MT decoupled from the PI3'K. Transgenic mice expressing MT-Y315/322F in the mammary gland develop widespread hyperplasias and solitary tumors that arise after a long latency period (Webster et al., 1998) . Consistent with the role of the PI3'K in providing cell survival function, the mammary epithelial hyperplasias derived from these mutant PyV MT mice exhibit elevated levels of apoptotic cell death (Webster et al., 1998) . Moreover inducible expression of a dominant negative inhibitor of the PI3'K in a mammary tumor line expressing PyV MT result in the induction of apoptotic cell death. Interestingly, tumor progression in these mutant PyV MT strains is correlated with the dramatic upregulation of the ErbB-2/ErbB-3 receptor tyrosine kinases (Webster et al., 1998) . Given the ability of ErbB-3/ ErbB-2 heterodimer to recruit the PI-3' kinase, it conceivable that elevated expression of these RTKs compensates for the inability of the mutant PyV MT oncogene to associate and activate the PI-3' kinase. Taken together, these observations argue that activation of the PI-3' kinase plays a critical role in promoting tumor progression by providing cell survival signals.
Future perspectives
The use of transgenic mouse models to study oncogene mediated signal transduction has illustrated several important issues. Firstly, tumor progression in these strains often involves the occurrence of highly selected mutations in the transgene that oer important insight into the mechanism by which tumor induction occurs. The selection for activating mutations in the juxtatransmembrane region of ErbB-2 in MMTV/ErbB-2 strains and the reversion of Shc binding site in mutant PyV MT strains represent two prominent examples of this phenomenon. Another important lesson is the requirement for cooperation of distinct signaling pathways to facilitate oncogenic transformation. For example, induction of mammary tumors by the ErbB-2 and PyV middle T system appear to require the combination of number of signaling molecules, including Ras, Src and the PI-3' kinase. Although these MMTV based transgenic models will continue to provide important insight into molecular basis of breast cancer, the development of transgenic models which more closely recapitulate the human disease are needed. The future development of transgenic mice expressing activated oncogenes under the transcriptional control of endogenous promoter using knock in approaches should allow this issue to be addressed.
